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Strengths and limitations of this study
 ► The ODOACRE cohort includes 4139 patients, 481 of 
which are treatment naïve, who started a dolutegra-
vir (DTG)- based regimen in each of the participating 
centres, providing a real clinical practice scenario of 
the use of DTG in Italy.
 ► Another strength is the cumulative length of follow- 
up (6937 patient- years of follow- up),which, along 
with the clinical, laboratory and demographic data 
of such a large number of patients, allows us to 
thoroughly define the safety and tolerability of the 
regimens.
 ► A predominant feature of our cohort is that it is prev-
alently composed of highly treatment experienced 
patients.
 ► The main weakness of our study is that it only col-
lects routine clinical data and therefore some data 
could be missing in the analysis.
 ► Although a yearly update is planned, a delay exists 
between local data collection and availability of an 
updated central database.
AbStrACt
Purpose The Observational cohort for the study of 
DOlutegravir in Antiretroviral Combination REgimens 
(ODOACRE) cohort was established in Italy in 2016 to 
evaluate the overall efficacy and tolerability of dolutegravir 
(DTG)- based antiretroviral (ARV) regimens in clinical 
practice.
Participants The ODOACRE cohort enrols all adult HIV-
1- infected patients, both treatment- naïve and treatment- 
experienced, starting a DTG- based ARV regimen, in 11 
clinical centres in Italy from 2014.
Findings to date In recent years, various works by the 
ODOACRE cohort have been produced, demonstrating the 
high efficacy and tolerability of DTG- based ARV regimens 
in clinical practice, both in ART- naïve (in the setting of 
acute HIV-1 infection and late presenters patient) and 
experienced patients. We confirmed the virological 
efficacy of DTG- based regimens and we evaluated 
predictors of virological failure. We investigated cause of 
discontinuation and evaluated tolerability and metabolic 
profile of the regimens. Within these investigations, we 
explored particularly the use of DTG in simplification in 
two- drug regimen with either rilpivirine or lamivudine. We 
also compared DTG- based regimens with other integrase 
inhibitors in clinical practice.
Future plans To continue to study long- term efficacy and 
tolerability of DTG- based regimens is the purpose of the 
ODOACRE cohort.
IntroduCtIon
Since the introduction of combination 
antiretroviral therapy (cART) in the mid- 
1990s, the management of HIV infection 
has dramatically changed along with the 
natural history and the prognosis of the 
disease.1 For decades, the standard of cART 
has been the association of two nucleos(t)
ide reverse transcriptase inhibitors (N(t)
RTIs) with an anchor drug, namely, either a 
ritonavir- boosted protease inhibitor (PI/r) 
or a non- nucleoside reverse transcriptase 
inhibitor (NNRTI). Such standard three- drug 
regimen proved to be effective in the vast 
majority of cases, obtaining and stably main-
taining virological suppression and reducing 
the morbidity and mortality of HIV/AIDS. 
However, as longer follow- up data became 
available, clinician’s attention shifted towards 
the toxicity of these aforementioned classes of 
antiretroviral (ARV) agents, with events such 
as osteoporosis and dyslipidaemia becoming 
increasingly evident in clinical practice.2 3 The 
marketing of the first- generation integrase 
inhibitors (INIs) represented a new turning 
point, which gave clinicians a new class of 
UniversitÃƒÂƒÃ‚ÂƒÃƒÂ‚Ã‚ÂƒÃƒÂƒÃ‚Â‚ÃƒÂ‚Ã‚Â  degli Studi di Milano. Protected by copyright.
 o
n
 D
ecem
ber 5, 2019 at
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029960 on 2 December 2019. Downloaded from 
2 Ciccullo A, et al. BMJ Open 2019;9:e029960. doi:10.1136/bmjopen-2019-029960
Open access 
Figure 1 Enrolling centres of the ODOACRE cohort. (1) 
Infectious Diseases Unit, Catholic University of the Sacred 
Heart, Fondazione Policlinico Universitario Agostino Gemelli 
IRCCS, Rome. (2). Infectious Diseases Unit, DIBIC Luigi 
Sacco, University of Milan, Milan. (3) Division of Infectious 
Diseases, Department of Infectious Diseases, Luigi Sacco 
University Hospital, Milan. (4) Division of Tropical and 
Infectious Diseases, 'Careggi' Hospital, Florence. (5) 
Infectious Dermatology and Allergology Unit, IFO S. Gallicano 
Institute (IRCCS), Rome. (6) Department of Public Health and 
Infectious Diseases, Sapienza University of Rome, Rome. (7) 
University Division of Infectious Diseases, Siena University 
Hospital, Siena. (8) Clinic of Infectious Diseases, Azienda 
O.U. Ospedali Riuniti di Ancona, Ancona. (9) Department 
of Clinical and Experimental Medicine, University of 
Sassari, Sassari. (10) Infectious Disease Clinic, Department 
of Medicine and Science of Ageing, 'SS Annunziata' 
Hospital, Chieti. (11) Clinic of Infectious Diseases, Azienda 
Ospedaliero- Universitaria Policlinico, Modena.
molecules with a better tolerability profile compared 
with NNRTIs and PIs. The down sides were a low genetic 
barrier, the bis- in- die formulation of raltegravir (RAL) 
and the need for a pharmacological booster for elvite-
gravir (EVG), which hindered a vast use of these drugs as 
switch strategies in experienced patients.4
Dolutegravir (DTG), a second- generation INI, 
presented high efficacy in early clinical trials, along 
with minimal drug–drug interaction risk and overall 
favourable tolerability profile.5–7 DTG also presented a 
higher genetic barrier compared with first- generation 
INI8–10 and has become, since its introduction, one of 
the preferred choices by clinicians for both treatment- 
naïve and experienced patients.11 12 However, in recent 
years, observational studies showed conflicting data 
on DTG tolerability, with some cohorts reporting high 
rate of discontinuations of DTG- based regimens due to 
neuropsychiatric events.13 14 DTG has also been related to 
neural- tube defects in newborns of mothers in treatment 
with this drug.15 Moreover, concerns have been raised 
about weight gain16 and a decline in renal function in 
patients taking DTG,17 the latter a problem that could be 
related to the effect of DTG on organic cation transporter 
2 (OCT2).18 To further investigate DTG tolerability and 
to assess the efficacy of DTG- based in clinical practice, 
several Italian clinicians joined their efforts creating a 
large observational cohort analysing patients starting 
DTG in real- life scenario.
Cohort deSCrIPtIon
The Observational cohort for the study of DOlutegravir 
in Antiretroviral Combination REgimens (ODOACRE) 
was established in Italy in 2016 to evaluate the overall effi-
cacy and tolerability of DTG- based regimens in clinical 
practice. Initially, the cohort was composed of 6 centres 
but rapidly expanded; currently, the ODOACRE cohort is 
composed of 11 centres, representing some of the most 
populated areas of the country (figure 1). In Italy, DTG- 
based regimens has become one of the first- line regimens 
both in ARV- naïve patients and in treatment- experienced 
ones; moreover, DTG- based dual regimens are listed as 
possible switch strategies for both patients on standard 
three- drug regimen with a 2 NRTI- backbone, in order to 
reduce the risk of drug- related toxicity (‘NRTI- sparing’ 
approach) and in patients on PI- based or NNRTI- based 
strategies, in order to improve the metabolic profile 
and to reduce the risk of drug–drug interactions.19 The 
main objectives of the cohort are to assess the virolog-
ical efficacy of DTG in real clinical practice settings and 
to assess the overall tolerability of DTG- based regimens. 
Moreover, the ongoing widespread use of less- drug regi-
mens, following the results from clinical trials, showed 
promising results of DTG- based two- drug regimen both 
in treatment- experienced patients and in treatment- naïve 
subject.20–23 This fact has lead the ODOACRE cohort to 
focus on assessing the efficacy, safety and tolerability of 
DTG- based dual regimens (ie, DTG plus either rilpivirine, 
RPV, or lamivudine, 3TC) in clinical practice.
The ODOACRE cohort enrols all adult HIV-1- 
infected patients, both treatment- naïve and treatment- 
experienced, starting a DTG- based antiretroviral 
regimen in one of the enrolling centres. All patients 
signed informed consent for data collection. Children 
under 18 years of age and adults incapable of providing 
informed consent are excluded. At first visit, subjects are 
required to provide written informed consent to allow 
the input of their clinical, epidemiological and biolog-
ical data in the cohort’s database. Informed consent 
covers the use of clinical care data for research purposes, 
the record linkage of patient data with other databases 
and permission to collect patient biosamples for cell 
and pharmacogenomics analysis. The primary outcome 
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of the cohort is to evaluate the virological efficacy and 
safety of DTG in both treatment- naïve and treatment- 
experienced patients. The secondary outcomes include 
the assessment of tolerability, changes in immunolog-
ical, metabolic and inflammatory profile. Main statistical 
analyses are as follows: parametric and non- parametric 
test, as appropriate, to compare continuous and cate-
gorical values, survival analysis (ie, Kaplan- Meier esti-
mator) and regression analyses (Cox regression, linear 
and logistic, as appropriate). As of 31 December 2018, 
4139 patients have been enrolled in the cohort, prev-
alently male (72.5%), with a median age of 50.4 years 
(IQR 42.2–55.6). Full patients’ characteristics are shown 
in table 1. Median follow- up time was 19.7 months (IQR 
10.7–28.7), with a cumulative time of follow- up of 6937 
patient- years of follow- up (PYFU). Almost 90% of the 
enrolled naïve patients were on an ARV regimen made 
up of a 2- NRTI backbone plus DTG (39.3% with abacavir 
(ABC)+3 TC and 50.9% with emtricitabine (FTC) plus 
either tenofovir disoproxil fumarate (TDF) or tenofovir 
alafenamide (TAF)); conversely, less than two- thirds of 
the experienced subjects were on such standard regi-
mens (41.8% with ABC+3 TC and 16.9% with FTC plus 
TDF or TAF), while 16.6% switched to 3TC +DTG, 10.1% 
switched to a dual therapy with a PI plus DTG and 7.1% 
to RPV+DTG. Table 2 comprehends all the analysed ARV 
regimens. Interestingly, there is a small group of 25 treat-
ment -naïve patients on a dual regimen in our cohort; in 
this group, during 43.7 PYFU we observed just one viro-
logical failure (VF, defined as failure to achieve HIV-1 
RNA below 50 copies/mL after 6 months since ARV 
initiation) and four treatment discontinuations (TDs). 
The single patient who experienced VF was a 38- year- old 
woman starting DTG plus etravirine, presenting at 6 
months an HIV viral load of 280 000 copies/mL; she 
was then switched to FTC/TDF+DTG+ DRV/r, achieving 
virological suppression. These data are of particular 
interest since data on safety and tolerability of two- drug 
regimen in treatment- naïve patients are only recently 
being published with the 48- week results of the GEMINI 
trials.23
Each patient usually attends one of the centres for a 
routine check- up every 3–4 months or when a new clin-
ical event occurs, a new treatment is prescribed or a 
change in biological markers is observed. The overall 
3 years probability of maintaining the prescribed regimen 
was 57.0%. It is to be noted however that we considered 
as treatment interruption also the change of backbone 
while maintaining DTG or the optimisation to single 
tablet regimen (ie, from ABC/3TC+DTG to ABC/3TC/
DTG or from FTC/TDF to FTC/TAF). Discontinuation 
of the prescribed regimen was due to:
 ► Treatment simplification (41.9%).
 ► Toxicities (29.7%): gastrointestinal (GI) tract (11.7%), 
neuropsychiatric (11.0%), renal (2.3%), other toxici-
ties (1.6%), hypersensitivity reaction (3.1%).
 ► Virological failure (4.3%).
 ► Treatment intensification (1.2%).
 ► Drug–drug interaction (1.2%).
 ► Other reasons (21.6%): concern of cardiovascular 
disease (2.2%), death (1.4%), unspecified/unknown 
(18.0%).
There were significant differences in the causes of 
discontinuation between naïve and experienced patients, 
with almost two- thirds of naïve patients (64.6%) inter-
rupting for proactive switch compared with the 36.4% 
of experienced patients. It is to be noted that in the last 
2 years, both a single tablet regimen with ABC/3TC/DTG 
and a coformulation of FTC with TAF (instead of TDF) 
became widely available in Italy, prompting clinicians to 
further simplify ARV regimens.
Variables collected at patient enrolment include ages, 
gender, country of origin, mode of HIV transmission, 
date of primary infection if available and first positive HIV 
test. At baseline and at each follow- up visit, the following 
information are collected: body weight, viroimmunolog-
ical markers of HIV infection such as CD4+ cell count, 
CD4/CD8 ratio and plasma HIV-1 RNA level, complete 
blood cell counts, lipid and liver enzymes; creatinine 
value and estimated glomerular filtration rate, antiret-
roviral drug start and stop dates, and the reasons for 
changing drug regimens, prophylaxis of opportunistic 
infections and comedications, serological and virolog-
ical data on coinfection with hepatitis C virus and hepa-
titis V virus; date and type of AIDS and non- AIDS events 
(including cardiovascular events, cancers, neuropsychi-
atric events, bacterial infections and so on), changes in 
bone mineral density (dual- energy X- ray absorptiometry 
(DEXA) scan), date and cause of death (if applicable). 
In this regard, we recently published a work analysing 
trends of hospitalisation in HIV- infected patients.24 
During 6937 PYFU, we observed 363 virological failures 
(described as two- consecutive HIV-1 RNA determination 
>50 copies/mL or a single HIV-1 RNA >1000 copies/mL 
in patients who previously achieved virological suppres-
sion or as failure to achieve HIV-1 RNA below 50 copies/
mL after 6 months since ARV initiation in treatment- 
naïve patients), with an overall incidence of 5.2 VF per 
100 PYFU.
Currently, the ODOACRE cohort aims at collabo-
rating with other European cohorts and databases, 
collecting data on HIV resistance mutations in order 
to further investigate DTG sensibility and efficacy in 
the context of resistance- associated mutations (RAMs). 
Preliminary collaboration with the ‘Euresist cohort’ led 
to a recent work showing that genotypic susceptibility 
score was a predictor of virological failure in INI- based 
regimens.25 Future projects also included the collection 
of biological samples to study HIV- DNA, inflammation 
markers (such as sCD14, interleukin 6, annexins and 
so on).
Patient and public involvement
The patients had no role in the design, recruitment and 
conduct of the study.
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Table 1 Patients’ characteristics at last available update (31 December 2018)
Variables Overall n=4139 (%)
Treatment- 
experienced n=3658 
(%) Naive n=481 (%) P values
Male, n (%) 2979 (72.5) 2609 (71.7) 370 (78.7) 0.001
Age (years), median (IQR) 50.4 (42.2–55.6) 51.0 (43.8–56.0) 41.3 (33.2–50.4) <0.001
Risk factor, n (%) <0.001
  MSM 1540 (37.9) 1310 (36.4) 230 (50.1)
  Eterosexual 1572 (38.7) 1416 (39.3) 156 (34.0)
  IDU 753 (18.5) 712 (19.8) 41 (9.0)
  Other/Unknown 196 (4.9) 164 (4.6) 32 (6.9)
HCVc Ab positive, n (%) 833 (21.2) 804 (22.8) 29 (7.3) <0.001
HBsAg positive, n (%) 107 (2.7) 96 (2.7) 11 (2.7) ns
CDC stage C, n (%) 837 (26.9) 774 (28.0) 63 (17.8) <0.001
Years from HIV diagnosis, median (IQR) 14.0 (5.4–23.1) / /
Zenith HIV- RNA (log10 copies/mL), median 
(IQR)
4.82 (4.29–5.37) 4.82 (4.29–5.36) 5.05 (4.57–5.56) <0.001
Nadir CD4+ (cells/mmc), median (IQR) 194.0 (61.0–324.0) 191.0 (58.0–312.0) 272.0 (94.5–488.5) <0.001
BL CD4+ (cell/mmc), median (IQR) 583 (365-810) 601 (400-823) 330 (110-560) <0.001
Years on cART, median (IQR) 10.6 (4.0–18.5) / /
Time on virological suppression (months), 
median (IQR)
43.9 (8.4–97.0) / /
Virologically suppressed patients at baseline, 
n (%)
2222 (80.4) / /
Previous virological failure, n (%) 1183 (44.9) / /
Therapies before switch, n (%) /
  2NRTI+PI 944 (25.9)
  2NRTI+INI 835 (22.9)
  2NRTI+NNRTI 702 (19.2) /
  Mono/Dual 763 (20.9)
  Others 405 (11.1)
Reasons for previous treatment 
discontinuation, n (%)
/
  Virological failure 209 (5.7)
  Treatment Intensification 106 (2.9)
  Dyslipidaemia 247 (6.8) /
  Proactive switch/Simplification 1773 (48.5)
  GI toxicity 170 (4.6)
  Renal toxicity 113 (3.1)
  Neurological toxicity 34 (0.9)
  Osteopoenia/Osteoporisis 61 (1.7)
  Other toxicity 44 (1.2)
  Hypersensitivity 20 (0.5)
  Drug–drug interactions 155 (4.2)
  Other/Unknown 723 (19.8)
GI, gastrointestinal; INI, integrase inhibitor; NNRTI, non- nucleoside reverse transcriptase inhibitor ; NRTI, nucleoside reverse transcriptase 
inhibitor ; PI, protease inhibitor.
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Table 2 ARV regimens in the cohort
ARV regimen Overall Treatment- experienced patients Naïve patients
DTG+ABC/3TC 1718 (41.5) 1529 (41.8) 189 (39.3)
DTG+FTC/Tenofovir (either TDF or TAF) 863 (20.9) 618 (16.9) 245 (50.9)
DTG+3TC 616 (14.9) 608 (16.6) 8 (1.7)
DTG+RPV 263 (6.4) 259 (7.1) 4 (0.8)
DTG+PI (boosted or unboosted) 380 (9.2) 370 (10.1) 10 (2.1)
DTG monotherapy 8 (0.2) 8 (0.2) 0
Other DTG- based dual regimen 22 (0.5) 19 (0.5) 3 (0.6)
Other DTG- based regimen (three or more drugs) 269 (6.5) 247 (6.8) 22 (4.6)
ARV, antiretroviral; DTG, dolutegravir; PI, protease inhibitor; RPV, rilpivirine; TAF, tenofovir alafenamide ; 3TC, lamivudine; TDF, tenofovir 
disoproxil fumarate.
Findings to date
In recent years, various works by the ODOACRE cohort 
have been produced and published in full paper arti-
cles. The cohort’s production has been mainly focused 
on the study of the effectiveness and tolerability of DTG- 
based ARV regimens. In 2017, we published a work on 
the safety of a switch strategy with DTG plus a dual- NRTI 
backbone,26 following reports of high rates of discontin-
uations of DTG- based regimens due to neuropsychiatric 
symptoms. In our work, we observed no virological fail-
ures during 1090 patient- months of follow- up and a 9.2% 
rate of TD, with a median time to TD of 81 days.
Baldin et al27 compared a switch regimen with FTC/
TDF plus DTG with a single tablet regimen with EVG 
and found that the 48- week estimated probability of 
continuing treatment was 74.5% for patients in the DTG 
group and 84.7% for those in the EVG group, and the 
difference was not statistically significant. Most recent 
works, meanwhile, mainly focus on the efficacy and safety 
of less drug regimens as switch strategies in virologically 
suppressed HIV-1- positive patients, since clinician’s atten-
tion has shifted towards the analysis of risk/benefit ratio 
of dual therapies. Capetti et al28 have described the effec-
tiveness and tolerability of a dual therapy with RPV and 
DTG, with a median follow- up time of 101 weeks; in this 
study, the probability of maintaining virological suppres-
sion was 96.3% at week 96 while also observing a signifi-
cant reduction of the low- density lipoprotein cholesterol/
high- density lipoprotein cholesterol ratio. Similarly, a 
work by Borghetti et al29 showed the results of our expe-
rience with a switch regimen of 3TC plus DTG in clin-
ical practice; in this study, over 216.5 PYFU, we observed 
five virological failures with a probability of maintaining 
suppression of 95.1% at week 96. Finally, a comparison 
between the switch regimens of RPV+DTG and 3TC+DTG 
was published in 201830; in this work, we observed no 
differences in the rate of virological failure between the 
two groups with no mutations to INI and with just one 
patient who developed a resistance mutation to NNRTIs 
at failure in the RPV group.
Rescue regimen in highly treatment-experienced patients
Our experience with highly treatment- experienced 
patients was well described in a work by Capetti et al,31 
showing the results of a rescue regimen of boosted 
darunavir plus DTG on 130 patients; about 90% of them 
had documented resistance to one to five ARV classes. 
After 48 weeks of follow- up, we observed a decrease in the 
proportion of patients harbouring active HIV replication 
from 40% at baseline to 6.1%. Patients starting boosted 
DRV+DTG with HIV- RNA over 50 copies/mL presented 
a success rate of 88.5%; meanwhile, 97.4% of those who 
started this regimen with HIV- RNA below 50 copies/mL 
maintained virological suppression.
DTG in naïve patient
Following the results from the GEMINI trials,23 the 
use of a dual therapy with 3TC plus DTG in treatment- 
naïve patients will become more common in clinical 
practice and we expect to describe the feasibility of this 
strategy in our centres in the short future. With these 
data obviously still months away, our experience in naïve 
patients is represented by two recent studies: Rossetti et 
al32 described the efficacy of DTG- based regimens (vs 
non- DTG- containing regimens) in achieving virological 
suppression in advanced HIV- infected naïve patients. 
Thirty- six per cent of patients in the DTG group achieved 
HIV- RNA below 50 copies/mL after 1 month of therapy 
(vs 17% of the non- DTG group) and 91% of them 
achieving suppression at 24 months (vs 89%), while the 
frequency of IRIS was similar between groups. Another 
study by Lagi et al33 compared the tolerability and viroim-
munologic efficacy of DTG- based regimens versus other 
regimens in naïve patients with acute HIV infection, with 
both groups showing significant increase in CD4+ cell 
count and CD4+/CD8+ ratio at 3, 6, 12, 24 and 36 months 
without significant differences between them.
Further study plans
Given the large data set available, the ODOACRE cohort 
aims at continuing its observational activity on DTG- 
based regimens, highlighting rates and reasons of DTG 
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discontinuation for both standard three- drug regimen 
and dual regimen, with a focus also on ARV- naïve patients. 
The already published data, confirming the favourable 
metabolic profile of DTG, will be implemented with the 
assessment of inflammation and immunological status. 
Moreover, given the expanding interest in weight gain 
during INI- based regimens,16 34 the cohort will attempt to 
thoroughly study this matter in its large population. The 
collaboration with other cohorts, mainly collecting data 
on HIV genotypic test, will lead to investigate the role 
of RAMs on the virological outcome of DTG- containing 
regimens, also considering not only HIV- RNA but also 
HIV- DNA. Additional assessments will also be conducted 
on the adverse events reported during therapy with DTG 
in order to examine possible predictors of these events 
(ie, neuropsychiatric events).
Strengths and limitations
The main strength of the ODOACRE cohort is that it 
enrols all the patients starting a DTG- based regimen in 
each of the participating centres, with a grand total of 
4139 patients as of December 2018, providing a real clin-
ical practice scenario of the use of DTG in Italy. Another 
strength is the cumulative length of follow- up (6937 
PYFU), which, along with the clinical, laboratory and 
demographic data of such a large number of patients, 
allows us to thoroughly define the safety and tolerability 
of the regimens. Our observational data on the dual 
therapy with RPV and DTG have anticipated the results 
of the SWORD trials; similarly, while the TANGO trials on 
the efficacy and tolerability of 3TC+DTG are still under 
way,35 our group has already described in multiple works 
the real- life feasibility of the said regimen.
A predominant feature of our cohort is that it is prev-
alently composed of highly treatment- experienced 
patients, with an overall median time from HIV diagnosis 
of 15.6 years (IQR 7.2–23.9), a median time on ARV of 
11.4 years (IQR 5.0–18.7) and a median time of virological 
suppression of 3.9 years (IQR 0.8–8.2). Moreover, 44.9% 
of the patients experienced at least one virological failure 
in their clinical history and 21.2% of them switched to 
DTG coming from a dual/mono regimen.
The main weakness of our study is that it only collects 
routine clinical data and therefore some data could be 
missing in the analysis. The observational nature of the 
study is prone to bias due to unmeasured confounders 
that may impact on the study endpoints. Inaccurate 
or incomplete reporting on non- AIDS- related events, 
concomitant medications and reasons for DTG discon-
tinuation cannot be excluded. Furthermore, as in several 
other observational studies, patients who refused to give 
their consent to data collection may differ systematically 
on some of the baseline characteristics from patients who 
participated.
Moreover, although a yearly update is planned, a delay 
exists between local data collection and availability of an 
updated central database.
CollAborAtIon
Data can be obtained on reasonable request. We 
encourage other clinical centres, even from other coun-
tries, to collaborate with our cohort. In particular, we aim 
to further investigate DTG- based regimens in several clin-
ical contests and we would like to evaluate these regimens 
in comparison with other INIs and other ARV drugs in 
order to try to answer the many questions that still come 
from clinical practice.
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